EGFR expression

In vivo and ex vivo PAI BP was moderately to highly correlative to percent area IHC EGFR expression (r = 0.65 and 0.54, p < 0.05, respectively) and the in vivo 100 J/cm2 treatment group demonstrated significantly lower BP than the controls. PAI emerges as a promising tool for tracking early molecular changes in HNC, with potential clinical applications.

The nanoparticle was developed by transfection of four plasmids (Gag-Cas9, Gag, sgRNA, VSV-G Azi) into 293T cells to form a type of bionanoparticle and modifying it with a targeted polymer material (DBCO-PEG-FA), and it showed a cancer-targeted property, faster cancer cellular uptake, higher gene editing efficiency with lower off-target effects, and therapy efficacy in mice, indicating a translational prospect. In conclusion, the study provides a recombinant bionanoparticle in vitro expressing a Cas9 gene editing system and offers a potential strategy for gene therapy of EGFR mutant lung cancer.

P1/2, N=144, Recruiting, Engeneic Pty Limited | Not yet recruiting --> Recruiting

Molecular docking results showed that ertugliflozin had the strongest intermolecular binding to EGFR and that ertugliflozin improved the viability of high-glucose (HG)/high-lipid combined hypoxia-reoxygenation-injured (HG/HP + H/R) cardiomyocytes and inhibited EGFR expression in cardiomyocytes...Molecular docking and cell experiments further confirmed that SGLT2i-ERTU improves HG/HP + H/R myocardial cell injury by targeting EGFR. Our study deepened the pharmacological mechanism of SGLT2is in the treatment of T2DM combined with CHD and provided a new perspective and therapeutic basis for future experimental research and healthcare.

P=N/A, N=200, Recruiting, Dalian Medical University First Affiliated Hospital; Dalian Medical University First Affiliated Hospital

P2/3, N=737, Not yet recruiting, Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center

P1, N=444, Not yet recruiting, Fudan University Shanghai Cancer Center; CSPC Zhongqi Pharmaceutical Technology Co., Ltd.

P1, N=36, Not yet recruiting, Shanghai East Hospital; Jing Medicine Technology (Shanghai) Co., Ltd.

We targeted T and NK92 ACDVs to cancer cells possessing the xenoantigen, N-glycolyl neuraminic acid GM3 ganglioside, using the 14f7hT antibody or the tumour antigen, epidermal growth factor receptor, using the nimotuzumab antibody...14F7hT-conjugated NK92 ACDVs showed cytotoxic activity against chronic lymphocytic leukaemia biopsies. This research shows the potential for using antibody-conjugated, cytotoxic T and NK ACDVs as a feasible and effective approach for tumour-targeted immunotherapy.

The multimodal therapeutic approach included one attempted VAC cycle (discontinued due to Grade 4 neutropenia), five cycles of single-agent doxorubicin, and subsequent administration of toceranib with dose reduction for anemia...Postmortem extended immunohistochemistry demonstrated heterogeneous receptor tyrosine kinase (RTK) expression: EGFR and VEGFR positivity, strong membranous HER2 labeling in approximately 60% of tumor cells, low KIT expression, and negative PDGFR. This case underscores the aggressive metastatic nature of primary hepatic hemangiosarcoma following rupture and highlights practical considerations for systemic therapy selection and adverse event monitoring in clinical practice.

EGF/EGFR expression is associated with immunosuppressive microenvironments and adverse outcomes in HGG. Radiomics may provide a non-invasive approach for estimating EGFR expression, although model performance requires external validation and EGFR-ADCs showed partial inhibitory activity within the tested range, though potency remains to be defined.These findings suggest a framework into radiogenomic stratification and targeted therapy in GBM.

Berberine altered the microtubule cytoskeleton similarly to vincristine...Their relationship to berberine and its derivatives is novel. Berberine-type compounds may be new candidates against cancer; however, they may develop drug resistance.